[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Savelkoul et al., 2015 - Google Patents

Choice and design of adjuvants for parenteral and mucosal vaccines

Savelkoul et al., 2015

View HTML
Document ID
7829831503889638854
Author
Savelkoul H
Ferro V
Strioga M
Schijns V
Publication year
Publication venue
Vaccines

External Links

Snippet

The existence of pathogens that escape recognition by specific vaccines, the need to improve existing vaccines and the increased availability of therapeutic (non-infectious disease) vaccines necessitate the rational development of novel vaccine concepts based on …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Savelkoul et al. Choice and design of adjuvants for parenteral and mucosal vaccines
Luchner et al. TLR agonists as vaccine adjuvants targeting cancer and infectious diseases
Wang et al. Better adjuvants for better vaccines: Progress in adjuvant delivery systems, modifications, and adjuvant–antigen codelivery
Toussi et al. Immune adjuvant effect of molecularly-defined toll-like receptor ligands
Levast et al. Vaccine potentiation by combination adjuvants
Fedele et al. Invasion of dendritic cells, macrophages and neutrophils by the Bordetella adenylate cyclase toxin: a subversive move to fool host immunity
Shirai et al. Lipid nanoparticle acts as a potential adjuvant for influenza split vaccine without inducing inflammatory responses
Rapaka et al. Using adjuvants to drive T cell responses for next-generation infectious disease vaccines
Jie et al. CpG ODN1826 as a promising mucin1-maltose-binding protein vaccine adjuvant induced DC maturation and enhanced antitumor immunity
Grabowska et al. Liposomal nanovaccine containing α-galactosylceramide and ganglioside GM3 stimulates robust CD8+ T cell responses via CD169+ macrophages and cDC1
Akache et al. Anti-IgE Qb-VLP conjugate vaccine self-adjuvants through activation of TLR7
Soegiarto et al. Challenges in the Vaccination of the Elderly and Strategies for Improvement
Zhu et al. Promising adjuvants and platforms for influenza vaccine development
Yan et al. The promise and challenges of cyclic dinucleotides as molecular adjuvants for vaccine development
Zhang et al. The positive correlation of the enhanced immune response to PCV2 subunit vaccine by conjugation of chitosan oligosaccharide with the deacetylation degree
Pogostin et al. Novel vaccine adjuvants as key tools for improving pandemic preparedness
Kim et al. Annona muricata L.-derived Polysaccharides as a potential adjuvant to a dendritic cell-based vaccine in a Thymoma-bearing model
Tukhvatulin et al. Adjuvantation of an influenza hemagglutinin antigen with TLR4 and NOD2 agonists encapsulated in poly (D, L-lactide-Co-glycolide) nanoparticles enhances immunogenicity and protection against lethal influenza virus infection in mice
Lirussi et al. Cyclic di-adenosine monophosphate: a promising adjuvant candidate for the development of neonatal vaccines
Wilson et al. Biodegradable PLGA-b-PEG nanoparticles induce T helper 2 (Th2) immune responses and sustained antibody titers via TLR9 stimulation
Romano et al. A structural view at vaccine development against M. tuberculosis
George et al. The potency of an anti-MERS coronavirus subunit vaccine depends on a unique combinatorial adjuvant formulation
Gaglio et al. Efficiency of chitosan nanocarriers in vaccinology for mucosal immunization
Lee et al. Precision Vaccinology Approaches for the Development of Adjuvanted Vaccines Targeted to Distinct Vulnerable Populations
Stark et al. Homologous prime-boost vaccination with OVA entrapped in self-adjuvanting archaeosomes induces high numbers of OVA-specific CD8+ T cells that protect against subcutaneous B16-OVA melanoma